

The “One-Two Punch” of Isoprenoids to Inflammation

Huanbiao Mo*

Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76204, USA

A large body of evidence from recent studies has shown that tocotrienols, the vitamin E molecules with an unsaturated farnesyl side chain, have potential in the prevention and/or treatment of cancer, metabolic syndrome, obesity, diabetes, osteoporosis, and neurodegeneration [1]. These activities of tocotrienols may converge on the emerging finding that tocotrienols suppress the activation of nuclear factor kappa B (NFκB), a major mediator in chronic inflammation that is gaining recognition as one of the main mechanisms underlying these chronic diseases. Tocotrienol-mediated inhibition of NFκB DNA binding activity or suppression of tumor necrosis factor α- and lipopolysaccharide-induced NFκB expression has been demonstrated in human breast cancer cells [2,3], colon carcinoma cells [4], malignant melanoma cells [5], pancreatic cancer cells [6], gastric cancer cells [7], metastatic oral cancer cells [8], adipocytes [9], and macrophages [10]. Moreover, the *in vitro* NFκB-suppressive activity of tocotrienols was borne out in gastric cancer [7] and pancreatic cancer [11] in nude mice. Readers are referred to recent reviews [12-14] for more details on the anti-inflammatory activity of tocotrienols.

A closer examination of the NFκB-suppressive activity of tocotrienols revealed a more fundamental biological activity of tocotrienols; NFκB suppression may be a secondary effect of tocotrienol-mediated down-regulation of another biochemical pathway that is ubiquitous in virtually all eukaryotic cells: the mevalonate pathway [15]. The mevalonate pathway operating in sterologenic tissues provides – in addition to cholesterol that is an essential component of cell membrane and a precursor to vitamin D, bile acids and steroid hormones-essential intermediates including farnesyl- and geranylgeranyl- pyrophosphates for the post-translational prenylation of growth-related proteins such as Ras and nuclear lamins and N-linked glycosylation of insulin-like growth factor receptor I. Most importantly, prenylated Ras activates NFκB [16].

The rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, is under a multivalent regulation consisting of sterol-mediated transcriptional feedback inhibition and a non-sterol-mediated post-transcriptional down-regulation. Tocotrienols suppress HMG CoA reductase at both transcriptional and post-transcriptional levels [17] and consequently, deplete the pool of prenyl pyrophosphates required for the prenylation of Ras and inactivate NFκB. Ahn et al. showed that tocotrienol-mediated ablation of NFκB activity was reversed by supplemental mevalonate, the product of the reaction catalyzed by HMG CoA reductase [15], establishing mevalonate deprivation as the primary cause for NFκB inactivation.

Tocotrienols may represent a broad class of isoprenoids encompassing approximately 23,000 mevalonate-derived end-products of plant secondary metabolism. Isoprenoids can be classified based on the number of isoprene units they contain, e.g. monoterpene (2x), sesquiterpene (3x), diterpene (4x), triterpene (6x) and polyterpene (Nx) [18]. In addition to these “pure” isoprenoids, the “mixed” isoprenoids including the tocotrienols have non-mevalonate-derived moieties. Assorted isoprenoids have a wide spectrum of functions in the plant kingdom, ranging from growth regulation to insect attraction, pollination assistance, and pest resistance. Fruits, vegetables and grains are the main sources of dietary isoprenoids.

The HMG CoA reductase-suppressive activity is extensively

observed among isoprenoids [19]. It is therefore no coincidence that a number of isoprenoids under investigation also suppress NFκB activity. The monoterpene limonene inhibited NFκB activation in human HL60 clone 15 leukemia cells [20] while an oxidative product of limonene, perillyl alcohol, suppressed NFκB in B-lymphoma cells [21]. A third monoterpene, geraniol, suppressed 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced inflammatory responses and up-regulation of NFκB and COX-2 in mice [22]. A sesquiterpene β-ionone inhibited tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced NFκB activation in human HepB3 and HepG2 hepatocellular carcinoma cells [23]. Various sesquiterpene lactones blocked NFκB activity [24]. Diterpene coronarin D suppressed NFκB activation in human KBM-5 chronic myeloid leukemia and A293 embryonic kidney carcinoma cells [25]. Garcinol, a polyisoprenylated benzophenone, inhibited the activation of NFκB in human BxPC-3 and Panc-1 pancreatic cancer cells [26] and squamous cell carcinoma of the head and neck [27]. Lastly, a triterpene lupeol suppressed TPA-induced activation of NFκB in CD-1 mice [28].

More support for the mevalonate-inflammation connection is drawn from studies with the statins, competitive inhibitors of HMG CoA reductase, and protein prenyl transferase inhibitors showing their parallel impacts on NFκB. Simvastatin inhibited NFκB activation in human COLO 205 colon cancer cells [29], squamous cell carcinoma SCC4 cells and KBM-5 cells [30]. Statins also suppressed the tumor necrosis factor α- [31] and receptor activator of NFκB ligand (RANKL) - [32] induced activation of NFκB in RAW 264.7 macrophages. C-reactive protein-induced NFκB activation was inhibited by simvastatin in human umbilical vein endothelial cells; reminiscent of the findings by Ahn et al. with tocotrienols [15], mevalonate attenuated the simvastatin effect on NFκB [33]. Consequent to Ras inactivation [34], farnesyl transferase inhibitors FTI-276 and SCH 66336 suppressed NFκB activation in rheumatoid arthritis synovial fibroblasts [35], human Jurkat T-cell lymphoma cells, H1299 lung adenocarcinoma cells, MCF-7 breast adenocarcinoma cells, and A293 embryonic kidney cells [34].

By depleting mevalonate and consequently suppressing NFκB activity, isoprenoids and most prominently tocotrienols may deliver a “one-two punch” to inflammation. The omnipresence of the mevalonate pathway and the critical role of inflammation in chronic disorders suggest that dietary isoprenoids warrant further investigation for their potential roles in the prevention and managing of chronic diseases.

*Corresponding author: Huanbiao Mo, Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76204, USA, Tel: 940-898-2712; E-mail: hmo@mail.twu.edu

Received August 24, 2013; Accepted August 24, 2013; Published August 26, 2013

Citation: Mo H (2013) The “One-Two Punch” of Isoprenoids to Inflammation. J Nutr Disorders Ther 3: e109. doi:10.4172/2161-0509.1000e109

Copyright: © 2013 Mo H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

1. Tocotrienols: vitamin E beyond tocopherols (2013) In: Tan B, Watson RR, Preedy VR (Eds.), (2nd edn), Boca Raton, FL: CRC Press, 2013.
2. Loganathan R, Selvaduray KR, Nesaretnam K, Radhakrishnan AK (2013) Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity. *Cell Prolif* 46: 203-213.
3. Shah SJ, Sylvester PW (2005) Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. *Exp Biol Med* (Maywood) 230: 235-241.
4. Xu WL, Liu JR, Liu HK, Qi GY, Sun XR, et al. (2009) Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells. *Nutrition* 25: 555-566.
5. Chang PN, Yap WN, Lee DT, Ling MT, Wong YC, et al. (2009) Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. *Nutr Cancer* 61: 357-366.
6. Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, et al. (2011) Vitamin E δ -tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF- κ B activation in pancreatic cancer. *Mol Cancer Ther* 10: 2363-2372.
7. Manu KA, Shanmugam MK, Ramachandran L, Li F, Fong CW, et al. (2012) First evidence that δ -tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF- κ B pathway. *Clin Cancer Res* 18: 2220-2229.
8. Kani K, Momota Y, Harada M, Yamamura Y, Aota K, et al. (2013) γ -tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF- κ B-regulated anti-apoptotic gene products. *Int J Oncol* 42: 75-82.
9. Matsunaga T, Shoji A, Gu N, Joo E, Li S, et al. (2012) γ -Tocotrienol attenuates TNF- α -induced changes in secretion and gene expression of MCP-1, IL-6 and adiponectin in 3T3-L1 adipocytes. *Mol Med Rep* 5: 905-909.
10. Wang Y, Jiang Q (2013) γ -Tocotrienol inhibits lipopolysaccharide-induced interleukin-6 and granulocyte colony-stimulating factor by suppressing C/EBP β and NF- κ B in macrophages. *J Nutr Biochem* 24: 1146-1152.
11. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, et al. (2010) γ -Tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. *Cancer Res* 70: 8695-8705.
12. Kaileh M, Sen R (2010) Role of NF- κ B in the anti-inflammatory effects of tocotrienols. *J Am Coll Nutr* 29: 334S-339S.
13. Nesaretnam K, Meganathan P (2011) Tocotrienols: inflammation and cancer. *Ann N Y Acad Sci* 1229: 18-22.
14. Kannappan R, Gupta SC, Kim JH, Aggarwal BB (2012) Tocotrienols fight cancer by targeting multiple cell signaling pathways. *Genes Nutr* 7: 43-52.
15. Ahn KS, Sethi G, Krishnan K, Aggarwal BB (2007) Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. *J Biol Chem* 282: 809-820.
16. Norris JL, Baldwin AS Jr (1999) Oncogenic Ras enhances NF- κ B transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. *J Biol Chem* 274: 13841-13846.
17. Song BL, DeBose-Boyd RA (2006) Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by delta- and gamma-tocotrienols. *J Biol Chem* 281: 25054-25061.
18. Elson CE, Peffley DM, Hentosh P, Mo H (1999) Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. *Proc Soc Exp Biol Med* 221: 294-311.
19. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. *Exp Biol Med* (Maywood) 229: 567-585.
20. Hirota R, Roger NN, Nakamura H, Song HS, Sawamura M, et al. (2010) Anti-inflammatory effects of limonene from yuzu (*Citrus junos* Tanaka) essential oil on eosinophils. *J Food Sci* 75: H87-92.
21. Berchtold CM, Chen KS, Miyamoto S, Gould MN (2005) Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. *Cancer Res* 65: 8558-8566.
22. Khan AQ, Khan R, Qamar W, Lateef A, Rehman MU, et al. (2013) Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP Kinase and NF- κ B. *Exp Mol Pathol* 94: 419-429.
23. Kim MO, Moon DO, Kang CH, Kwon TK, Choi YH, et al. (2010) beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF- κ B activity. *Mol Cancer Ther* 9: 833-843.
24. Siedle B, Garcia-Piñeres AJ, Murillo R, Schulte-Monting J, Castro V, et al. (2004) Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF- κ B. *J Med Chem* 47: 6042-6054.
25. Kunnumakkara AB, Ichikawa H, Anand P, Mohankumar CJ, Hema PS, et al. (2008) Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis. *Mol Cancer Ther* 7: 3306-3317.
26. Parasramka MA, Gupta SV (2011) Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. *Nutr Cancer* 63: 456-465.
27. Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, et al. (2013) Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. *Cancer Prev Res* 6: 843-854.
28. Saleem M, Afaq F, Adhami VM, Mukhtar H (2004) Lupeol modulates NF- κ B and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. *Oncogene* 23: 5203-5214.
29. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, et al. (2007) Simvastatin inhibits NF- κ B signaling in intestinal epithelial cells and ameliorates acute murine colitis. *Int Immunopharmacol* 7: 241-248.
30. Ahn KS, Sethi G, Aggarwal BB (2007) Simvastatin potentiates TNF- α -induced apoptosis through the down-regulation of NF- κ B-dependent antiapoptotic gene products: role of I κ B α kinase and TGF- β -activated kinase-1. *J Immunol* 178: 2507-2516.
31. Qureshi AA, Tan X, Reis JC, Badr MZ, Papsian CJ, et al. (2011) Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. *Lipids Health Dis* 10: 177.
32. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF- κ B pathway. *Int J Cancer* 123: 1733-1740.
33. Liang YJ, Shyu KG, Wang BW, Lai LP (2008) Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. *Cardiology* 110: 182-190.
34. Takada Y, Khuri FR, Aggarwal BB (2004) Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF- κ B activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF- κ B-regulated gene expression and up-regulation of apoptosis. *J Biol Chem* 279: 26287-26299.
35. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 130: 440-455.